181 related articles for article (PubMed ID: 16220064)
21. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.
Takai S; Miyazaki M
Am J Cardiovasc Drugs; 2006; 6(6):363-6. PubMed ID: 17192125
[TBL] [Abstract][Full Text] [Related]
22. [A novel synthesis of olmesartan medoxomil and examination of its related impurities].
Wu TZ; Liu XH; Zhang FL; Xie MH
Yao Xue Xue Bao; 2006 Jun; 41(6):537-43. PubMed ID: 16927829
[TBL] [Abstract][Full Text] [Related]
23. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
Chrysant SG; Chavanu KJ; Xu J
Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
[TBL] [Abstract][Full Text] [Related]
24. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
Brunner HR
J Hum Hypertens; 2002 May; 16 Suppl 2():S13-6. PubMed ID: 11967728
[TBL] [Abstract][Full Text] [Related]
25. Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats.
Nakamoto T; Harasawa H; Akimoto K; Hirata H; Kaneko H; Kaneko N; Sorimachi K
Eur J Pharmacol; 2005 Dec; 528(1-3):43-51. PubMed ID: 16336959
[TBL] [Abstract][Full Text] [Related]
26. Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.
Omboni S; Malacco E; Mallion JM; Fabrizzi P; Volpe M
High Blood Press Cardiovasc Prev; 2014 Mar; 21(1):1-19. PubMed ID: 24435506
[TBL] [Abstract][Full Text] [Related]
27. Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.
Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):255-263. PubMed ID: 28608025
[TBL] [Abstract][Full Text] [Related]
28. Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil.
Ferrario C
Vasc Health Risk Manag; 2009; 5(1):301-14. PubMed ID: 19436655
[TBL] [Abstract][Full Text] [Related]
29. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension.
Hazan L; Hernández Rodriguez OA; Bhorat AE; Miyazaki K; Tao B; Heyrman R;
Hypertension; 2010 Jun; 55(6):1323-30. PubMed ID: 20385971
[TBL] [Abstract][Full Text] [Related]
30. [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
Ishii M
Nihon Rinsho; 2004 Jan; 62(1):193-202. PubMed ID: 14737853
[TBL] [Abstract][Full Text] [Related]
31. Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists.
Smith DH
Am J Cardiovasc Drugs; 2007; 7(5):347-56. PubMed ID: 17953473
[TBL] [Abstract][Full Text] [Related]
32. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
Pugsley MK
Proc West Pharmacol Soc; 2005; 48():35-8. PubMed ID: 16416656
[TBL] [Abstract][Full Text] [Related]
33. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist.
Brunner HR; Nussberger J
J Hypertens Suppl; 2001 Jun; 19(1):S15-20. PubMed ID: 11451210
[TBL] [Abstract][Full Text] [Related]
34. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
[TBL] [Abstract][Full Text] [Related]
35. Olmesartan medoxomil for the treatment of hypertension in children and adolescents.
Tocci G; Volpe M
Vasc Health Risk Manag; 2011; 7():177-81. PubMed ID: 21490943
[TBL] [Abstract][Full Text] [Related]
36. An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy.
Takahashi T; Konta T; Takasaki S; Ichikawa K; Takeishi Y; Kubota I
Clin Exp Nephrol; 2007 Sep; 11(3):202-208. PubMed ID: 17891346
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy of olmesartan medoxomil.
Brunner HR; Laeis P
J Hypertens Suppl; 2003 May; 21(2):S43-6. PubMed ID: 12929907
[TBL] [Abstract][Full Text] [Related]
38. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?
Wehling M
Clin Ther; 2004; 26 Suppl A():A21-7. PubMed ID: 15291376
[TBL] [Abstract][Full Text] [Related]
39. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
Gorain B; Choudhury H; Kundu A; Sarkar L; Karmakar S; Jaisankar P; Pal TK
Colloids Surf B Biointerfaces; 2014 Mar; 115():286-94. PubMed ID: 24388859
[TBL] [Abstract][Full Text] [Related]
40. Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.
Paulis L; Becker ST; Lucht K; Schwengel K; Slavic S; Kaschina E; Thöne-Reineke C; Dahlöf B; Baulmann J; Unger T; Steckelings UM
Hypertension; 2012 Feb; 59(2):485-92. PubMed ID: 22215717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
